Načítá se...
Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
BACKGROUND: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. METHODS: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m(2). Background factors consi...
Uloženo v:
| Vydáno v: | Oncotarget |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Impact Journals LLC
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5922406/ https://ncbi.nlm.nih.gov/pubmed/29721212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24779 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|